Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07

Helbling, Daniel; Bodoky, G.; Gautschi, Oliver; Sun, Hong; Bosman, F.; Gloor, Beat; Burkhard, Roger; Winterhalder, Ralph; Madlung, Axel; Rauch, Daniel; Saletti, Piercarlo; Widmer, Lukas A.; Borner, Markus; Baertschi, D.; Yan, Ping; Benhattar, Jean; Leibundgut, Elisabeth Oppliger; Bougel, Stéphanie; Koeberle, Dieter

doi:10.1093/annonc/mds519

Cited by 76 publications

(43 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In einer Analyse von 58 an einem Zentrum mit einer definierten Therapie (50,4 Gy in Kombination mit Cetuximab, Capecitabin und Irinotecan) behandelten Patienten mit lokal fortgeschrittenem Rektumkarzinom war KRAS weder bezüglich der Tumorregression (pCR Rate) noch bezüglich des 3-Jahres-DFS prädiktiv [15]. Gleiches wurde bezüglich der Tumorregression bei 41 Patienten in einer belgischen Studie beobachtet [11], während in einer Analyse von 39 Patienten einer italienischen Studie zumindest eine Tendenz für bessere Tumorregression nachgewiesen wurde (p=0,12; [2] Eine weitere randomisierte Phase-II-Studie mit dem EGFR-mAB Panitumumab wurde von der SAKK berichtet (SAKK 41/07) [19]. Patienten mit zentral getesteten KRAS-Wildtyp-Tumoren und einem Tumorstadium cT3/4 und/ oder N+ wurden eingeschlossen.…”

Section: Einsatz Von Monoklonalen Antikörpern In Der Neoadjuvanten Raunclassified

Perioperative (Radio-)Chemotherapie des lokal fortgeschrittenen Rektumkarzinoms

Hofheinz

2015

Onkologe

View full text Add to dashboard Cite

Section: Einsatz Von Monoklonalen Antikörpern In Der Neoadjuvanten Raunclassified

Perioperative (Radio-)Chemotherapie des lokal fortgeschrittenen Rektumkarzinoms

Hofheinz

2015

Onkologe

View full text Add to dashboard Cite

“…The SAKK 41/07 trial analyzed panitumumab in combination with standard CRT in wild-type K-ras LARC [26]. A total of 68 patients were assigned to receive CRT with ( n = 40) or without ( n = 28) panitumumab (6 mg/kg every 2 weeks for 8 weeks).…”

Section: Egfr Inhibitionmentioning

confidence: 99%

The Addition of Target Therapy to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: A Review

Benevento

Felice²,

Musio³

et al. 2017

Chemotherapy

View full text Add to dashboard Cite

Currently, neoadjuvant fluoropyrimidine-based chemoradiotherapy (CRT) is standard practice in the management of locally advanced rectal cancer (LARC). In the last decade there has been a lively interest in the improvement of clinical outcomes by modifying this standard regimen by the addition of further agents. We review combinations of targeted therapies and conventional CRT currently under investigation in LARC patients.

show abstract

“…Median OS was 10.4 months (95% CI 9.4-11.6) with panitumumab and 10.0 months (95% CI 9.3-11.0) with cetuximab (HR 0.97, 95% CI 0.84-1.11) [28]. Panitumumab has been shown to induce pathological near complete response or complete response when given along with neoadjuvant concurrent radiation therapy in patients with KRAS wild-type locally advanced rectal cancer [29]. Panitumumab is generally well tolerated and has a similar side effect profile as cetuximab.…”

Section: Targeting Egfr or Other Kinasesmentioning

confidence: 99%

Targeted Therapy of Colorectal Cancer

Seeber

Gastl²

2016

Oncol Res Treat

View full text Add to dashboard Cite

Over the past decades, considerable progress has been made in the management of colorectal cancer (CRC), leading to a significant improvement in overall survival. Although part of this success has been rightly attributed to aggressive surgical management and advances in other adjunct treatments, our understanding of the pathogenesis of CRC and emergence of newer molecular targets for colon cancer has created a powerful impact. In this review article, we will discuss various targeted therapies in the management of metastatic CRC (mCRC). In particular, vascular endothelial growth factor (VEGF)- and epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies have become integral components of the first-line treatment strategies for mCRC. Newer agents on the horizon soon to be incorporated in clinical practice will be briefly reviewed as well. Currently, the only predictive biomarker for treatment selection in patients with mCRC is tumor RAS mutational status.

show abstract

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07

Abstract: The addition of panitumumab to neoadjuvant CRT in patients with KRAS wild-type LARC resulted in a high pNC/CR rate, mostly grade 3 DC. The results of both treatment arms exceeded prespecified thresholds. The addition of panitumumab increased toxicity.

Cited by 76 publications

References 42 publications

Perioperative (Radio-)Chemotherapie des lokal fortgeschrittenen Rektumkarzinoms

Perioperative (Radio-)Chemotherapie des lokal fortgeschrittenen Rektumkarzinoms

The Addition of Target Therapy to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: A Review

Targeted Therapy of Colorectal Cancer

Contact Info

Product

Resources

About